Project Grant R41CA302099
Award Date 9/18/25
Completion Date 8/31/26
Dollars Obligated $360K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77002, USA
Similar Awards
- This $300,002 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research at Baylor University to develop an innovative artificial intelligence (AI)-driven approach for accelerating the discovery of dual-targeted cancer theranostic agents. The research aims to develop bispecific small molecule inhibitory conjugates (BSMICs) targeting two critical enzymes in cancer cell fatty acid metabolism - stearoyl-CoA desaturase-1...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $285,599 Project Grant to Sinopia Biosciences Inc., a San Diego-based company specializing in computational drug discovery and metabolomics research. The grant will support the development of a metabolomics-enabled AI/ML platform for identifying new treatments to enhance drug sensitivity in cancer. The project aims to leverage high-throughput omics technologies, machine learning, and a chemical library of ~3,300...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This $414,803 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Massachusetts Institute of Technology (MIT) to develop improved T cell receptor (TCR) engineering strategies for TCR-T cell cancer immunotherapy. The key products and services to be delivered under this grant include: Implementing high-throughput library screens of TCR constant region variants to identify mutations that can improve TCR signaling strength, with...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $528,157 to The University of Texas MD Anderson Cancer Center to develop innovative AI-based methods for discovering and optimizing T cell receptors (TCRs) for use in T cell engager therapies and spatial TCR sequencing-based antigen discovery. Specifically, the project will use the researchers' existing "PMTNet-OMNI" deep learning...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded a $399,444 Project Grant to Cancure LLC (Canzx Biotherapeutics) on August 1, 2025. The funding will support a feasibility study of a novel agent that aims to stimulate NK (natural killer) and CD8 T cells for potential use in treating solid tumors. The study seeks to address challenges with persistence and sustained function of these cell-based therapies in the solid...
- The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...